NEW YORK (GenomeWeb News) – BGI-Shenzhen said today that it has completed its cash tender offer for Complete Genomics, setting the stage for the merger of the two firms to be finalized.

The offer, which has been delayed numerous times, expired at 11:59 EDT March 14. As of the expiration of the offer, the depositary for the offer indicated that 31.4 million shares, or 88 percent, of Complete's stock had been validly tendered and not withdrawn.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.